Patient Enrollment Completed for EFTISARC-NEO Phase II Trial

Immutep announced that patient enrollment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus pembrolizumab in the neoadjuvant setting for patients with resectable soft tissue sarcoma.